- Context Therapeutics ( NASDAQ: CNTX ) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday.
- The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor.
- Context ( CNTX ) will sponsor the trial while Menarini will supply elacestrant at no cost.
- CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year.
- CNTX stock gained 5.8% to $2 in premarket trading.
For further details see:
Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial